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ABSTRACT
Background and Objective: Studies are limited regard-
ing the impact of obesity on early erectile functional out-
comes after robotic radical prostatectomy. Our goal was to
determine this impact using patient-reported validated
questionnaires.
Methods: International Index of Erectile Function (IIEF-6)
scores were prospectively collected with institutional re-
view board approval, for patients who underwent robotic
radical prostatectomy with bilateral nerve sparing from
February 2007 to October 2009. The data were catego-
rized into nonobese and obese groups and subsequently
into 2 subgroups based on risk for postprostatectomy
erectile dysfunction. Low risk is preoperative IIEF-6 19
and high risk is IIEF-6 19. The groups and subgroups
were compared using chi-square analysis.
Results: Of 190 consecutive patients, 67 were excluded
for preoperative severe erectile dysfunction (IIEF-6 7),
or lack of IIEF-6 scores, or both. There were 69 nonobese
patients of which 88% were potent preoperatively and
20% regained potency at 12 months postoperatively. Of 54
obese patients, 85% were potent preoperatively and 25%
at 12 months. There was no difference in erectile function
recovery rates between the groups (P0.755). In both
groups, patients with low risk of postoperative erectile
dysfunction had statistically similar postoperative mean
IIEF-6 scores at 6 and 12 months (P0.580 and P0.389,
respectively), and no difference in erectile function recov-
ery rates existed at 12 months (P0.735).
Conclusion: Obesity has no major contribution to the
rate of early erectile function recovery after robotic radical
prostatectomy. Preoperative erectile function remains the
determining factor in postradical prostatectomy erectile
dysfunction.
Key Words: Radical prostatectomy, Sexual function re-
covery, Prostate cancer, Prostatectomy outcomes.
INTRODUCTION
Oncologic control, continence, and sexual functions (SF)
are outcomes monitored after treatment for localized pros-
tate cancer (CaP). Most of the treatment available for CaP
will however affect sexual quality of life. Often, men with
a healthy sexual life will choose the treatment method
with less effect on their sexual quality of life (QOL) for
fear of feeling less masculine, because the value sexual
potency holds in patients’ lives vary.1-3 Comorbidities,
such as obesity, hypertension, hyperlipidemia, diabetes,
and coronary artery disease can affect SF preoperatively,
and SF recovery postradical prostatectomy (RP) could be
subpar due to preoperatively impaired erectile hemody-
namics, significantly affecting QOL.
Obesity has been associated with increased risk of erectile
dysfunction (ED) by 30% to 90% due to its association
with metabolic syndrome (MS) recently associated with
male hypogonadism that leads to severe ED.4-6 Several
researchers have investigated the impact of obesity on
health-related quality of life (HRQOL) after RP and re-
ported that while obesity is generally correlated to lower
pre- and postsurgical HRQOL, the recovery rate of
HRQOL in obese men is similar to that of normal weight
men.7,8 In contrast, other studies have also reported ad-
verse effects on post open or laparoscopic radical prosta-
tectomy outcomes.9,10 However, the majority of these
HRQOL studies heavily investigate the impact of obesity
on urinary and bowel function recovery with less empha-
sis on erectile function recovery. In addition, the defini-
tions of potency used in the studies are inconsistent,
because the methods of measuring potency vary.
This study compares the impact of obesity on the recovery
of erectile function while considering preoperative po-
tency and using validated questionnaires, such as the
International Index of Erectile Function (Questions 1-5
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SCIENTIFIC PAPERand 15, also called IIEF-6) for an objective measure of
erectile function.11,12
MATERIALS AND METHODS
Institutional review board approval was obtained for a
prospectively collected database of patients who under-
went robotic-assisted laparoscopic radical prostatectomy
(RALP) with bilateral nerve sparing for localized prostate
cancer from February 2007 to October 2009. All proce-
dures were performed by a single surgeon (JCJ) whose
preferred method of radical prostatectomy is with robotic
technology.
JCJ is a fellowship-trained urologic oncologist with expe-
rience in open, conventional, and robotic radical prosta-
tectomy. He is currently the chief of robotic surgery at a
tertiary institution in Huntington, West Virginia. He has
performed over 1000 robotic cases, including over 700
robotic radical prostatectomy cases with unilateral and/or
bilateral nerve sparing, depending on disease involve-
ment. The antegrade method was used for the proximal
dissection while the apex and distal one-third was done
with the retrograde method.
Data collected included patients’ demographics, PSA,
prostate volume, prostate biopsy results, perioperative
variables, and pre- and postoperative IIEF-6 scores at 3, 6,
9, and 12 months. All IIEF-6 questionnaires were provided
to the patients during check-in by the secretary or nurse at
the registration desk. These forms were to be completed
by the patients without assistance and returned to the
nurse before leaving the clinic. These questionnaires be-
came part of patient’s medical records. The scores were
then collected and input into a database according to
postoperative months. An IIEF-6 score from a prior visit
was carried over to the next visit unless a new score
existed. Patients without preoperative IIEF-6 scores
and/or with severe preoperative erectile dysfunction (ED)
were excluded from the study. Erectile functions were
defined as severe ED (IIEF-6 7), moderate ED, (7-15)
mild ED, (16-21) and potent. (22-30) We designated pa-
tients with no or mild ED as “potent” and those with
moderate or severe ED as “impotent,” with or without
erectile aids. The data were stratified by body mass index
(BMI) and categorized into nonobese (BMI 30) and
obese (BMI 30) groups. Each group was subsequently
divided into 2 subgroups by risk of postprostatectomy ED.
Low risk is defined as preoperative IIEF-6 19 and high
risk is preoperative IIEF-6 19. Statistical analyses to com-
pare both groups and subgroups were performed using
Medcalc software for Windows version 11.1.1. All P values
were 2-tailed with a 95% confidence interval.
RESULTS
A total of 123 patients are included in the cohort compris-
ing of 69 nonobese and 54 obese men. Both groups were
similar in terms of patient demographics with the excep-
tion of BMI (Table 1). The mean BMI was 26.5kg/m
2 and
32.9kg/m
2, respectively (P0.0001). Erectile function reha-
bilitation program with low doses of phosphodiestrase-5
inhibitors (PDE5I) were recommended for all patients after
RALP, if they were preoperatively sexually active with or
without erectile aid and not contraindicated. They re-
ceived samples and prescriptions for these pharmacolog-
ical agents to take routinely and could be discontinued if
the patient no longer desired them. Overall, 72% of men in
the cohort had no ED preoperatively, while 15% had mild
ED and 13% moderate ED (overall preoperative po-
tency87.0%). Overall, the 12-month postoperative po-
tency rate among those who responded to the IIEF-6
questionnaire at that period was 22.5%. This percentage
improved to 27.1% if data were analyzed on preopera-
tively potent patients only. The distribution of the re-
covery rates by postoperative period over 12 months is
shown in Table 2.
The mean IIEF-6 scores recorded for each subgroup were
statistically similar at every postoperative period analyzed
for patients of all ages and for patients 60 years old
(Table 3). The percentage of patients who were potent at 12
months was statistically similar in both groups (Table 2, 4)
(P0.755), while the majority of the patients remained with
postprostatectomy ED. In low-risk patients, there was no
significant difference in potency rate between both
groups at 12 months (P0.735). This rate improved from
12.8% at 6 months to 24.4% at 12 months in the nonobese
patients comparable to 14.3% at 6 months to 31.0% at 12
months in the obese patients, with no statistically signifi-
cant difference in rates at each postoperative period. In
patients with a high-risk for postprostatectomy ED, the
recovery rate remained similar between the groups. As
expected, these patients remained relatively impotent at
12 months.
Since age plays a significant role in potency rates and
erectile hemodynamic changes, the data were re-analyzed
for preoperative potent men 60 years and younger. The
erectile function recovery rates as expected were higher in
patients 60 years old. Twenty-eight percent of the nono-
bese low-risk patients were potent at 12 months, statisti-
cally similar to 30% for the obese low-risk patients
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impotent but more importantly, there was no difference in
the erectile function recovery rate between the groups at
12 months.
DISCUSSION
Obesity has been associated with poor recovery after a surgical
procedure, starting with poor surgical wound healing to func-
Table 1.
Clinical and Demographic Data of 123 Patients in This Cohort Treated with Robotic-Assisted Laparoscopic Radical Prostatectomy
Nonobese Obese
bP
(BMI 30; n69) (BMI 30; n54)
Mean age, years (range) 61.1 (41–83) 60.3 (46–74) 0.536
BMI, kg/m
2 (SD) 26.5 (2.1) 32.9 (2.5) 0.0001
Mean preop IIEF-6 (SD) 25 (6.6) 24 (6.7) 0.407
No ED, n (%) 52 (75.4) 36 (66.7) 0.390
Mild ED, n (%) 9 (13.0) 10 (18.5) 0.557
Potent, n (%) 61 (88.4) 46 (85.2) 0.800
Moderate ED, n (%) 8 (11.6) 8 (14.8) 0.800
Comorbidities
Hypertension, n (%) 35 (50.7) 27 (50.0) 0.917
Diabetes, n (%) 5 (7.2) 6 (11.1) 0.664
Dyslipidemia, n (%) 22 (31.9) 8 (14.8) 0.048
CAD, n (%) 12 (17.4) 5 (9.3) 0.304
aCADcoronary artery disease; EDerectile dysfunction; SDstandard deviation.
bPearson’s 
2, P-values are 2-sided, and 0.05 is considered significant.
Table 2.
Erectile Function Recovery from Patient-Reported IIEF-6 Questionnaires Over a 12-Month Postsurgery Period
Postop Period Baseline 3 Months 6 Months 9 Months 12 Months
Nonobese
a
N 6 9 4 95 65 54 9
No ED, n (%) 52 (75.4) 2 (4.1) 5 (8.9) 3 (5.5) 6 (12.2)
Mild ED, n (%) 9 (13.0) 1 (2.1) 1 (1.8) 6 (10.9) 4 (8.2)
Potent, n (%) 61 (88.4) 3 (6.1) 6 (10.7) 9 (16.4) 10 (20.4)
Moderate ED, n (%) 8 (11.6) 6 (12.2) 12 (21.4) 10 (18.2) 14 (28.6)
Severe ED, n (%) 0 (0.0) 40 (81.6) 38 (67.9) 36 (65.5) 25 (51.2)
Obese
N 5 4 3 64 64 54 0
No ED, n (%) 36 (66.7) 1 (2.8) 3 (8.3) 3 (6.6) 5 (12.5)
Mild ED, n (%) 10 (18.5) 0 (0.0) 3 (8.3) 3 (6.6) 5 (12.5)
Potent, n (%) 46 (85.2) 1 (2.8) 5 (10.9) 6 (13.3) 10 (25.0)
Moderate ED, n (%) 8 (14.8) 5 (13.9) 7 (15.2) 10 (22.2) 9 (20.0)
Severe ED, n (%) 0 (0.0) 30 (83.3) 33 (71.7) 29 (64.4) 21 (52.5)
aEDerectile dysfunction.
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function by way of metabolic syndrome and low testosterone
levels, and as such erectile function recovery in the obese
patient continues to be an area of interest with HRQOL studies.
The impact of obesity on the outcomes of open, lapa-
roscopic, or robotic radical prostatectomy has been
extensively investigated but with inconsistent conclu-
sions. For instance, some studies have reported no
Table 3.
Mean IIEF-6 Scores by Preoperative Risk of Postprostatectomy Erectile Dysfunction
Low Risk High Risk
Nonobese Obese P
a Nonobese Obese P
a
Mean IIEF-6 (range) Mean IIEF-6 (range) Mean IIEF-6 (range) Mean IIEF-6 (range)
All Ages
Baseline 28 (19–30) 27 (20–30) 0.153 13 (7–17) 14 (8–17) 0.476
3 months 5 (1–27) 4 (1–24) 0.459 2 (1–7) 3 (1–9) 0.509
6 months 7 (1–28) 6 (1–30) 0.580 5 (1–13) 5 (1–16) 1.000
9 months 7 (1–24) 7 (1–30) 1.000 4 (1–9) 5 (1–16) 0.675
12 months 9 (1–30) 11 (1–30) 0.389 5 (1–12) 5 (1–16) 1.000
60 Years Old
Baseline 28 (20–30) 28 (21–30) 1.000 11 (7–17) 13 (9–17) 0.489
3 months 5 (1–22) 5 (1–24) 1.000 1 (1) 3 (1–6) 0.448
6 months 6 (1–22) 7 (1–30) 0.661 6 (2–13) 6 (1–16) 1.000
9 months 7 (1–22) 8 (1–30) 0.677 5 (2–9) 6 (1–16) 0.800
12 months 10 (1–30) 11 (1–30) 0.724 8 (3–12) 5 (1–16) 0.448
aStudent t test analysis, P-values 0.05 are considered significant, and all values are 2-sided.
Table 4.
Potency Percentages at 6 and 12 Months Post-RALP by Risk of Post-Prostatectomy Erectile Dysfuntion




















No ED, % 8.9/12.2 6.5/12.5 0.937/0.779 10.6/14.6 8.6/17.2 0.941/0.969
Mild ED, % 1.8/8.2 6.5/12.5 0.481/0.752 2.1/9.8 5.7/13.8 0.791/0.891 0.0/0.0 9.1/9.1 0.919/0.870
Moderate ED, % 21.4/28.6 15.2/22.5 0.586/0.682 19.1/26.8 11.4/20.7 0.523/0.762 33.3/37.5 27.3/27.3 0.842/0.978
Severe ED, % 67.9/51.0 71.7/52.5 0.842/0.942 68.1/48.8 74.3/48.3 0.715/0.840 66.7/37.5 63.6/63.6 0.744/0.510
Potent, % 10.7/20.4 13.0/25.0 0.960/0.793 12.8/24.4 14.3/31.00 0.896/0.735 0.0/0.0 9.1/9.1 0.919/0.870
Impotent, % 89.3/79.6 87.0/75.0 0.526/0.793 87.2/75.6 85.7/69.0 0.896/0.735 100/100 90.9/90.9 0.919/0.870
Age 60 years
No ED, % 6.5/10.7 10.3/14.8 0.948/0.959 7.1/12.0 13.6/20.0 0.775/0.748
Mild ED, % 3.2/14.3 3.4/11.1 0.496/0.961 3.6/16.0 0.0/10.0 0.909/0.882 0.0/0.0 14.3/14.3 0.646/0.646
Moderate ED, % 25.8/39.3 20.7/22.2 0.872/0.280 25.0/36.0 18.2/25.0 0.816/0.640 33.3/66.7 28.6/14.3 0.546/0.366
Severe ED, % 64.5/35.7 65.5/51.9 0.850/0.348 64.3/36.0 68.2/45.0 0.991/0.760 66.7/33.3 57.1/71.4 0.674/0.673
Potent, % 9.7/25.0 13.8/25.9 0.927/0.819 10.7/28.0 13.6/30.0 0.900/0.854 0.0/0.0 14.3/14.3 0.646/0.646
Impotent, % 90.3/75.0 86.2/74.1 0.927/0.816 89.3/72.0 86.4/70.0 0.900/0.854 100/100 85.7/85.7 0.646/0.646
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radical prostatectomy13,14 while others reported adverse
effects.9,10 It is important to note that in all these
HRQOL studies, the definitions of potency and how it is
measured, subjectively or objectively, vary to a great
extent. This leads to the inconsistent potency rates
reported for each surgical approach investigated. In this
study, we defined potency as IIEF-6 16 with or with-
out the use of pharmacological erectile aid. Our overall
potency in patients of all ages with available IIEF-6
score at 12 months postoperatively was 23%, 25% in
patients that are 60 years old. Although this potency
rate is low, it is within the range reported for 12-month
follow-up periods in the literature. Significant potency
recovery may still be possible at 36 to 40 months post-
surgery.15
The objective of this study was to investigate the impact
of obesity on erectile function recovery or potency rate
at postoperative periods. According to our analysis,
there is no significant difference in erectile function
recovery between nonobese and obese patients (all
P0.05). The preoperative potency in each group was
similar (Table 1), thus eliminating any bias that existed
preoperatively. We also divided the patients into 2
groups based on risk for postprostatectomy erectile
dysfunction, and the rates of erectile function recovery
remained similar between the nonobese and obese pa-
tients at every postoperative period up to 12 months (all
P0.05). Although we arrived at this conclusion with
data from patients of all ages, further analysis of data
from younger patients (60 years old) did not alter the
conclusion.
There are a few limitations in this study that should be
mentioned. The low attrition rate could be a significant
bias. The actual response rate for the 12-month IIEF-6
questionnaire was 54% in the nonobese group and 51% in
the obese group. Bringing forward IIEF-6 scores from
prior visits increased the response rate to 71% and 74%,
respectively. This practice of “worse case scenario” IIEF-6
scores, the majority being impotent, contributes to the low
overall potency rate in our study. The low number of
patients at each postoperative period could also lead to a
low statistical power to detect any significant difference
between the groups. The IIEF-6 questionnaires could be
mailed out but there were concerns of recalling biases
associated with these validated questionnaires.
Comorbidities mentioned in Table 1 could have an
impact on erectile function recovery as well. The ideal
test to investigate the impact of obesity in this study
would be a multivariate regression analysis to adjust for
the covariates. Another limitation is our inability to
determine if the IIEF-6 scores reported are with or
without PDE5I; therefore, it is possible that differences
in erectile function recovery exist between the groups if
analyzing IIEF-6 scores without PDE5I usage. Lastly,
since there is documented evidence of erectile function
recovery up to 40 months postoperatively,15 additional
studies with prolonged follow-up periods would be
invaluable.
CONCLUSION
The rate of early erectile function recovery after robotic-
assisted laparoscopic radical prostatectomy for localized
prostate cancer is similar in obese and nonobese patients,
irrespective of preoperative potency. Preoperative po-
tency status remains a higher risk factor for postprostate-
ctomy erectile dysfunction than obesity does.
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